Dependence on sales of electrolyzed hydrogen water ionizers
First written in FY2016. 9 of 11 entries say "Mitigated", first in FY2017. Latest entry: FY2026.
The whole theme swung hardest in 2024: 13 of 48 companies on the "Worse" side.
23 other companies' latest entry also says "Mitigated".
- FY2026MitigatedAnnual report
「The Group's main products are electrolyzed hydrogen water ionizers, which account for 38.7% of consolidated sales, and their water-purification cartridges, which account for 24.2%. The Group's business performance remains highly dependent on the ionizer-related business.」
The ionizer share of consolidated sales declined from 41.0% in the previous fiscal year to 38.7%, while the cartridge share declined from 25.0% to 24.2%, indicating further diversification into the bottled water and medical-related businesses. - 2026-05-13MitigatedFinancial results presentation
「Total water-ionizer revenue 9,077 40.4% 9,242 38.3% +165 +1.8%」
Water-ionizer revenue declined as a share of total revenue from 40.4% to 38.3%, indicating lower dependence on water ionizers in the revenue mix. - FY2025MitigatedAnnual report
「The Group's main products are electrolyzed hydrogen water ionizers, which account for 41.0% of consolidated sales, and their water-purification cartridges, which account for 25.0%. The Group's business performance remains highly dependent on the ionizer-related business. Water-purification cartridge sales provide a stable earnings base that is relatively resistant to external factors, but if operating activities related to ionizers were disrupted for any reason, the Group's business and performance could be affected. To strengthen its earnings base, the Group is working to grow businesses other than ionizers, including bottled water in the Water Healthcare business and the medical-related business. As these businesses grow, the ionizers' share of sales is declining and the risk is being reduced.」
Ionizers accounted for 41.0% of sales and cartridges for 25.0%. The company explained that growth in the bottled water and medical-related businesses was reducing dependence on ionizers. - FY2024MitigatedAnnual report
「The Group's main products are electrolyzed hydrogen water ionizers, which account for 45.1% of consolidated sales, and their water-purification cartridges, which account for 26.2%. The Group's business performance remains highly dependent on the ionizer-related business. Water-purification cartridge sales provide a stable earnings base that is relatively resistant to external factors, but if operating activities related to ionizers were disrupted for any reason, the Group's business and performance could be affected. To strengthen its earnings base, the Group is working to grow businesses other than ionizers, including bottled water in the Water Healthcare business and the medical-related business. As these businesses grow, the ionizers' share of sales is declining.」
Ionizers accounted for 45.1% of sales and cartridges for 26.2%. The company explained that growth in businesses other than ionizers was reducing dependence on ionizers alone. - FY2023RestatedAnnual report
「The Group's main products are electrolyzed hydrogen water ionizers, which account for 45.5% of consolidated sales, and their water-purification cartridges, which account for 28.2%. The Group's business performance remains highly dependent on the ionizer-related business.」
The Group has reaffirmed its recognition that it remains highly dependent on the ionizer-related business, with ionizers and cartridges accounting for 45.5% and 28.2% of sales, respectively. - FY2022MitigatedAnnual report
「The Group's main products are electrolyzed hydrogen water ionizers and their water-purification cartridges. Although the ionizers' share of sales is declining as the Group's businesses grow, the Group remains highly dependent on the ionizer-related business. Water-purification cartridge sales currently account for approximately 30% of consolidated sales and provide a stable earnings base that is relatively resistant to external factors. However, if operating activities related to ionizers were disrupted for any reason, the Group's business and performance could be affected.」
The Group stated that it remains highly dependent on the ionizer-related business, while water-purification cartridges have become a stable earnings base accounting for approximately 30% of consolidated sales, providing a relative diversification of dependence. - FY2021MitigatedAnnual report
「In the fiscal year ended March 2021, electrolyzed hydrogen water ionizers generated ¥6,758 million, or 45.3% of sales, while cartridges generated ¥4,774 million, or 32.0%.」
The ionizer share of sales declined from 48.1% in the previous fiscal year to 45.3%, while the share of cartridges and other products increased, further reducing dependence on ionizers alone. - FY2020MitigatedAnnual report
「The following are sales and sales composition by product for the most recent 3 consolidated fiscal years. In the fiscal year ended March 2020, electrolyzed hydrogen water ionizers generated ¥7,754 million, or 48.1% of sales; cartridges generated ¥4,511 million, or 28.0%; and Other generated ¥3,850 million, or 23.9%.」
The ionizer share of sales declined to 48.1%, while the share of other products and businesses expanded, reducing dependence on ionizers alone. - FY2018MitigatedAnnual report
「The Group's main products are electrolyzed hydrogen water ionizers, which are medical devices. They account for a high proportion of sales each fiscal year, and the Group's business performance depends on these ionizers.」
The electrolyzed hydrogen water ionizer share of sales declined from 60.0% to 53.8%, while cartridges rose from 25.5% to 29.5%, reducing the relative level of dependence. - FY2017MitigatedAnnual report
「Electrolyzed hydrogen water ionizers: fiscal year ended March 2016, ¥9,834 million, 64.4%; fiscal year ended March 2017, ¥9,147 million, 60.0%.」
Dependence on the core ionizer business continued, although its share of sales declined from 64.4% to 60.0%. - FY2016First statedAnnual report
「Our main products are electrolyzed hydrogen water ionizers, which are medical devices. They account for a high proportion of sales each fiscal year, and our business performance depends on these ionizers.」
Sales of electrolyzed hydrogen water ionizers totaled ¥9,834 million in the fiscal year ended March 2016, accounting for 64.4% of sales.